Adicet Bio Inc
ACET · NASDAQ
Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of 'off-the-shelf' gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.
Market Data
Price
$7.96
+0.35 (+4.60%)
Market Cap$73M
P/E Ratio—
EPS$—
52W High$17.44
52W Low$6.41
Beta1.53
Data from Finnhub · Updated Mar 10, 2026